Seoulin Bioscience Co.Ltd (038070) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.78 Billion ≈ $1.88 Million USD) by net assets (₩86.36 Billion ≈ $58.53 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Seoulin Bioscience Co.Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)

This chart illustrates how Seoulin Bioscience Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 038070 current and long-term liabilities for a breakdown of total debt and financial obligations.

Seoulin Bioscience Co.Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
New Century Logistics (BVI) Limited Ordinary Shares NASDAQ:NCEW	0.782x
Canacol Energy Ltd. TO:CNE	0.124x
Milux Corporation Bhd KLSE:7935	0.023x
NEW STRATUS ENERGY F:80N	N/A
OCR Group Bhd KLSE:7071	-0.107x
HUBLine Bhd KLSE:7013	0.134x
PT Sarimelati Kencana Tbk JK:PZZA	0.150x
Redwood Group Ltd TWO:8426	-0.002x

Annual Cash Flow Conversion Efficiency for Seoulin Bioscience Co.Ltd (2013–2024)

The table below shows the annual cash flow conversion efficiency of Seoulin Bioscience Co.Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Seoulin Bioscience Co.Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩83.89 Billion ≈ $56.85 Million	₩-4.61 Billion ≈ $-3.13 Million	-0.055x	-590.65%
2023-12-31	₩83.06 Billion ≈ $56.29 Million	₩930.57 Million ≈ $630.63K	0.011x	+121.55%
2022-12-31	₩83.79 Billion ≈ $56.78 Million	₩-4.36 Billion ≈ $-2.95 Million	-0.052x	-143.64%
2021-12-31	₩74.86 Billion ≈ $50.73 Million	₩8.92 Billion ≈ $6.04 Million	0.119x	+93.73%
2020-12-31	₩59.92 Billion ≈ $40.61 Million	₩3.68 Billion ≈ $2.50 Million	0.061x	-49.85%
2019-12-31	₩59.71 Billion ≈ $40.46 Million	₩7.32 Billion ≈ $4.96 Million	0.123x	+57.79%
2018-12-31	₩53.72 Billion ≈ $36.40 Million	₩4.17 Billion ≈ $2.83 Million	0.078x	+207.51%
2017-12-31	₩51.49 Billion ≈ $34.90 Million	₩1.30 Billion ≈ $881.84K	0.025x	-55.42%
2016-12-31	₩48.60 Billion ≈ $32.94 Million	₩2.76 Billion ≈ $1.87 Million	0.057x	-37.62%
2015-12-31	₩45.30 Billion ≈ $30.70 Million	₩4.12 Billion ≈ $2.79 Million	0.091x	+43.12%
2014-12-31	₩43.14 Billion ≈ $29.24 Million	₩2.74 Billion ≈ $1.86 Million	0.063x	-46.57%
2013-12-31	₩41.57 Billion ≈ $28.17 Million	₩4.94 Billion ≈ $3.35 Million	0.119x	--

About Seoulin Bioscience Co.Ltd

KQ:038070 Korea Biotechnology

Market Cap

$37.75 Million

₩55.70 Billion KRW

Market Cap Rank

#22893 Global

#1589 in Korea

Share Price

₩6310.00

Change (1 day)

-0.47%

52-Week Range

₩6050.00 - ₩8390.00

All Time High

₩36786.63